

Alina Iovleva

List of Publications by Year in descending order

Source: [//exaly.com/author-pdf/4119264/publications.pdf](https://exaly.com/author-pdf/4119264/publications.pdf)

Version: 2024-02-01

13
papers

586
citations

1032804

8
h-index

1098140

12
g-index

13
all docs

13
docs citations

13
times ranked

1161
citing authors

#	ARTICLE	IF	CITATIONS
1	The ecology of extended-spectrum β -lactamases (ESBLs) in the developed world. <i>Journal of Travel Medicine</i> , 2017, 24, S44-S51.	3.0	189
2	Carbapenem-Resistant Enterobacteriaceae. <i>Clinics in Laboratory Medicine</i> , 2017, 37, 303-315.	1.5	171
3	Therapies for multidrug resistant and extensively drug-resistant non-fermenting gram-negative bacteria causing nosocomial infections: a perilous journey toward "molecularly targeted" therapy. <i>Expert Review of Anti-Infective Therapy</i> , 2018, 16, 89-110.	4.5	63
4	Structural Basis of Reduced Susceptibility to Ceftazidime-Avibactam and Cefiderocol in <i>Enterobacter cloacae</i> Due to AmpC R2 Loop Deletion. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	3.4	57
5	Carbapenem-Resistant <i>Acinetobacter baumannii</i> in U.S. Hospitals: Diversification of Circulating Lineages and Antimicrobial Resistance. <i>MBio</i> , 2022, 13, e0275921.	4.3	37
6	<i>In Vitro</i> Evolution of Cefiderocol Resistance in an NDM-Producing <i>Klebsiella pneumoniae</i> Due to Functional Loss of CirA. <i>Microbiology Spectrum</i> , 2021, 9, e0177921.	3.0	34
7	Characterization of KPC-82, a KPC-2 Variant Conferring Resistance to Ceftazidime-Avibactam in a Carbapenem-Nonsusceptible Clinical Isolate of <i>Citrobacter koseri</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, e0015021.	3.4	13
8	High-Level Carbapenem Resistance in OXA-232-Producing <i>Raoultella ornithinolytica</i> Triggered by Ertapenem Therapy. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 64, .	3.4	12
9	Reduced ceftazidime and ertapenem susceptibility due to production of OXA-2 in <i>Klebsiella pneumoniae</i> ST258. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 2203-2208.	3.2	5
10	Reduced Ertapenem Susceptibility Due to OXA-2 Production in <i>Klebsiella pneumoniae</i> ST258. <i>Open Forum Infectious Diseases</i> , 2017, 4, S128-S128.	0.9	2
11	636. Genome Epidemiology of Carbapenem-Resistant <i>Acinetobacter baumannii</i> (CRAb) in the United States. <i>Open Forum Infectious Diseases</i> , 2019, 6, S295-S295.	0.9	2
12	Isolation and Characterization of Lytic Bacteriophages Targeting Diverse <i>Enterobacter</i> spp. Clinical Isolates. <i>Phage</i> , 2022, 3, 50-58.	2.1	1
13	Frequency of cefiderocol heteroresistance among patients treated with cefiderocol for carbapenem-resistant <i>Acinetobacter baumannii</i> infections. <i>JAC-Antimicrobial Resistance</i> , 2024, 6, .	2.1	0